Thrombolytic Science is focused on developing a proprietary product, M5, a mutant of pro-urokinase (proUK).  M5 is a thrombolytic that follows a different paradigm than tPA, has superior efficacy and is accompanied by little bleeding risk.

The Breakthrough

M5 is a novel thrombolytic that is more effective than current drugs and has a much lower bleeding risk since it spares hemostatic fibrin.

M5’s safety profile will permit a far greater utilization of therapeutic thrombolysis than is now possible.

M5 is especially well-suited to fulfill two major vascular unmet needs:

1) A thrombolytic compatible with percutaneous coronary intervention (PCI).  Critical coronary reperfusion will not need to be delayed by the time-consuming door-to-balloon time currently required for PCI.

2)Ischemic stroke, as a safe and effective treatment with double the current treatment window.